Loading patent…
AssigneeChugai Seiyaku Kabushiki Kaisha
InventorsToshihiko Ohtomo, Takayoshi Tanaka, Yasuo Sugitani
Estimating the term…
The present invention provides a method for determining the efficacy of a GPC3-targeting therapeutic agent for a liver cancer patient and a GPC3-targeting therapeutic agent or a preparation which is to be administered to a patient for whom it has been determined that the GPC3-targeting therapeutic agent is effective. The present invention provides, for example, a method for determining that a GPC3-targeting therapeutic agent is effective when the expression level of GPC3 per tumor cell is a predetermined value, and a GPC3-targeting therapeutic agent or a preparation which is to be administered to a patient for whom it has been determined that the GPC3-targeting therapeutic agent is effective.
A method for determining the efficacy of an anti-GPC3 antibody for liver cancer in a patient, the method comprising measuring an expression level of GPC3 indicated by immunofluorescent quantification digital slide (IQD) cell score in a biological sample isolated from the patient, wherein the anti-GPC3 antibody is determined to be effective when the expression level of GPC3 indicated by IQD cell score in the biological sample is higher than 22000.
A method for selecting a patient for which an anti-GPC3 antibody is effective from a patient group with liver cancer, the method comprising the step of determining that the anti-GPC3 antibody is effective for a patient when the expression level of GPC3 indicated by IQD cell score in a biological sample isolated from the patient is higher than 22000 in IQD cell score.
A method for treating liver cancer, comprising administering an anti-GPC3 antibody to a patient having an expression level of GPC3 per tumor cell indicated by IQD cell score in a biological sample isolated from the patient is higher than 22000 in IQD cell score.
Dependencies are inferred from the claim text.